Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Pharm Fr. 2013 Jul;71(4):225-33. doi: 10.1016/j.pharma.2013.04.001. Epub 2013 May 28.

Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: the example of Alzheimer's disease.

Author information

1
Institut Galien Paris-Sud, UMR CNRS 8612, faculté de pharmacie, université Paris-Sud, 5, rue Jean-Baptiste-Clément, 92296 Châtenay-Malabry cedex, France. karine.andrieux@u-psud.fr

Abstract

Targeting of the central nervous system (CNS) in order to treat disorders is actually challenging due to the necessity to cross the blood brain barrier (BBB). This review aims to show how nanomedicine can propose new approach for the treatment and the diagnosis of CNS diseases focusing on Alzheimer's disease (AD). AD is a neurodegenerative disorder prevalent in the senile population. It is characterized by severe neuronal loss and proliferation of plaques composed of β-amyloid peptide (Aβ) and Tau protein deposites. An imbalance between production and clearance leading to the aggregation of Aβ peptides especially in neurotoxic forms, may be the initiating factor in AD. The absence of an effective therapeutic approach nowadays could be, in part, due to the bad knowledge of AD physiopathology and the lack of early diagnosis. Many drawbacks such as poor bioavailability or limited BBB arising of tested molecules in the current or new therapeutic strategies explain their failure but can be resolved by the use of nanotechnology. Examples of recently published works using nanoparticles for improving diagnosis and therapy of AD are presented. Ideal nanocarriers for this aim must be able to pass through the BBB and to interact with an AD marker as soluble extracellular Aβ forms which are known as the most toxic ones. These first results, even if many ones were obtained in vitro, brought to light the potential of nanoparticles for this challenging issue.

KEYWORDS:

Alzheimer; Brain diseases; Diagnosis; Diagnostic; Maladies cérébrales; Nanomedicine; Nanomédecine; Nanoparticles; Nanoparticules; Traitement; Treatment

PMID:
23835020
DOI:
10.1016/j.pharma.2013.04.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Masson (France)
    Loading ...
    Support Center